These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24142600)

  • 21. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experiences with basal analogue insulin in routine care. Retrospective follow up analysis of a database from daily routine care].
    Sudár Z; Muth L; Nyirati C; Szí V; Tornóczky J; Ulrich G
    Orv Hetil; 2013 Sep; 154(37):1476-84. PubMed ID: 24016754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary.
    Reynolds LR
    Postgrad Med; 2010 Jan; 122(1):201-3. PubMed ID: 20107306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study.
    Wadsworth TG; Carr GG; Madaras-Kelly K; Remington R; Bell J
    Am J Health Syst Pharm; 2021 Feb; 78(5):401-407. PubMed ID: 33354715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN; Dündar N; Eren E
    J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
    Hanefeld M; Fleischmann H; Schiffhorst G; Bramlage P
    Diabetes Technol Ther; 2014 Apr; 16(4):241-6. PubMed ID: 24229089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
    Pieber TR; Treichel HC; Hompesch B; Philotheou A; Mordhorst L; Gall MA; Robertson LI
    Diabet Med; 2007 Jun; 24(6):635-42. PubMed ID: 17381500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.